Bone Biologics (OTC:BBLG) Stock Rating Reaffirmed by EF Hutton Acquisition Co. I

Bone Biologics (OTC:BBLG – Get Rating)‘s stock had its “buy” rating restated by equities researchers at EF Hutton Acquisition Co. I in a research note issued to investors on Thursday, Benzinga reports. They presently have a $2.25 price objective on the stock. Bone Biologics Price Performance OTC BBLG traded down $0.01 on Thursday, hitting $0.24. […]

Related Keywords

, Bone Biologics Corporation , Ef Hutton Acquisition Co , Bone Biologics Co , Bone Biologics Company Profile , Bone Biologics , Get Rating , Street Group , Biologics Corporation , Bone Biologics Daily , Otc Bblg , Bblg , Medical , Reiterated Rating , Ef Hutton Acquisition Co I ,